Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy... Show more
INDP moved above its 50-day moving average on September 08, 2026 date and that indicates a change from a downward trend to an upward trend. In 26 of 30 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 87%.
The Momentum Indicator moved above the 0 level on September 08, 2026. You may want to consider a long position or call options on INDP as a result. In 80 of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for INDP just turned positive on August 20, 2026. Looking at past instances where INDP's MACD turned positive, the stock continued to rise in 39 of 49 cases over the following month. The odds of a continued upward trend are 80%.
Following a +33.17% 3-day Advance, the price is estimated to grow further. Considering data from situations where INDP advanced for three days, in 160 of 210 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The 50-day moving average for INDP moved below the 200-day moving average on August 26, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INDP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
INDP broke above its upper Bollinger Band on September 08, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for INDP entered a downward trend on August 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. INDP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (32.051) is normal, around the industry mean (19.994). P/E Ratio (0.000) is within average values for comparable stocks, (27.689). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.527). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (427.627).
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INDP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology